ORPHA:454723
Endometrioid carcinoma of ovary
Publications
18,422
97.2th percentile
Trials
66
Interventional, condition-specific
Researchers
1,557
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare malignant epithelial tumor of ovary characterized by confluent or cribriform proliferations of round, oval, or tubular glands, typically lined by stratified non-mucin-containing epithelium with well-defined luminal margins. Squamous differentiation, secretory changes, oxyphilic variants, sex cord-stromal type patterns, or sertoliform endometrioid carcinomas may occur. Patients most commonly present in the sixth decade of life, either with a pelvic mass with or without pain, or without any symptoms. The tumor may be bilateral and is frequently associated with endometriosis and/or endometrial carcinoma.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006335
- UMLS:C0346163
- NCIT:C7979
Additional Mondo synonyms (12)
endometrioid adenocarcinoma of ovary · endometrioid adenocarcinoma of the ovary · endometrioid cancer of ovary · endometrioid cancer of the ovary · endometrioid carcinoma of ovary · endometrioid carcinoma of the ovary · endometrioid ovary carcinoma · endometrium adenocarcinoma of ovary · ovarian endometrioid adenocarcinoma · ovarian endometrioid cancer · ovarian endometrioid carcinoma · ovary endometrium adenocarcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
18,422 matched papers (11,196 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
66 matched on ClinicalTrials.gov (9 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
14
Drugs / clinical candidates · MONDO_0006335
- OLAPARIB·phase 3
- ABEMACICLIB·phase 2
- BEVACIZUMAB·phase 2
- LETROZOLE·phase 2
- NIRAPARIB·phase 2
- PACLITAXEL·phase 2
- PALBOCICLIB·phase 2
- PAMIPARIB·phase 2
- SENAPARIB·phase 2
- TEMOZOLOMIDE·phase 2
- TISLELIZUMAB·phase 2
- PEMBROLIZUMAB·phase 1
- SECLIDEMSTAT·phase 1
- PLATINUM·early phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
18,422
18,422 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
18,422 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
11,196 in the last 10 years · high confidence · 97.2th percentile (publications denominator)
Phrase hits: 18,422 · MeSH hits: 0
Who's working on it?
1,557
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y8 papers · 2026
Department of Gynecology, Hebei General Hospital, Shijiazhuang, China.
Papers in Europe PMC - 02Li Y7 papers · 2026
Department of Laboratory Medicine, Tinglin Hospital of Jinshan District, Shanghai, 201505, People's Republic of China.
Papers in Europe PMC - 03Wang L7 papers · 2026
Department of Hematology, The First Affiliated Hospital of Naval Medical University (Changhai Hospital), Naval Medical University, Shanghai, People's Republic of China.
Papers in Europe PMC - 04Wang X7 papers · 2026
Department of Gynecology, Hebei General Hospital, Shijiazhuang, China.
Papers in Europe PMC - 05Liu Y6 papers · 2026
School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou 510515, China.
Papers in Europe PMC - 06Zhang J6 papers · 2026
Department of Obstetrics and Gynecology, University of Vermont Medical Center, Burlington, VT, USA.
Papers in Europe PMC - 07Chen Y4 papers · 2026
Liaoning Provincial Core Lab of Glycobiology and Glycoengineering, College of Basic Medical Science, Dalian Medical University, Dalian, Liaoning, China.
Papers in Europe PMC - 08Li J4 papers · 2026
Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
Papers in Europe PMC - 09Liu J4 papers · 2026
School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. liujy@wyu.edu.cn.
Papers in Europe PMC - 10Liu X4 papers · 2026
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
66
interventional trials for this specific condition
66 interventional trials matched this specific condition name; 9 currently recruiting in our sample.
Data as of 11 September 2026
66 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 97.9th percentile).
high confidence · 97.9th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
66 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05920798·RECRUITING·Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Not reviewed·Conditions: Fallopian Tube Carcinosarcoma · Primary Peritoneal Carcinosarcoma · Recurrent Fallopian Tube Carcinoma · Recurrent Fallopian Tube Clear Cell Adenocarcinoma·Matched via name phrase
- NCT06639074·RECRUITING·Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Not reviewed·Conditions: Advanced Fallopian Tube Carcinoma · Advanced Fallopian Tube High Grade Serous Adenocarcinoma · Advanced Ovarian Carcinoma · Advanced Ovarian Carcinosarcoma·Matched via name phrase
- NCT05231122·RECRUITING·Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Not reviewed·Conditions: Ovarian Clear Cell Adenocarcinoma · Platinum-Sensitive Ovarian Carcinoma · Recurrent Endometrial Serous Adenocarcinoma · Recurrent Fallopian Tube Carcinoma·Matched via name phrase
- NCT05950464·RECRUITING·Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
Not reviewed·Conditions: Recurrent Endometrial Carcinoma · Recurrent Endometrial Clear Cell Adenocarcinoma · Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma·Matched via name phrase
- NCT06466382·RECRUITING·OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
Not reviewed·Conditions: Ovarian Neoplasm Epithelial · Fallopian Tube Neoplasms · Ovarian Endometrioid Carcinoma · High-grade Serous Ovarian Carcinoma (HGSOC)·Matched via name phrase
- NCT05415709·RECRUITING·Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer
Not reviewed·Conditions: Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma · Ovarian Endometrioid Adenocarcinoma·Matched via name phrase
- NCT04111978·RECRUITING·MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Not reviewed·Conditions: Ovarian Neoplasm Epithelial · Fallopian Tube Neoplasms · Peritoneal Neoplasms · High-grade Serous Ovarian Carcinoma (HGSOC)·Matched via name phrase
- NCT04575935·RECRUITING·Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Not reviewed·Conditions: Advanced Ovarian Carcinoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Tumor · Fallopian Tube Serous Neoplasm·Matched via name phrase
- NCT04919629·RECRUITING·APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Not reviewed·Conditions: Fallopian Tube Carcinosarcoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Serous Adenocarcinoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- isrctn·ISRCTN09180474·No longer recruiting·BriTROC1 (The UK Translational Research in Ovarian Cancer Collaborative) - Sample collection study in recurrent high grade serous ovarian cancer (HGSOC)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10356387·No longer recruiting·ICON8 Trials Programme
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Endometrioid carcinoma of ovary — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Endometrioid carcinoma of ovary" OR "Endometrioid carcinoma of the ovary" OR "endometrioid adenocarcinoma of ovary" OR "endometrioid adenocarcinoma of the ovary" OR "endometrioid cancer of ovary" OR "endometrioid cancer of the ovary" OR "endometrioid ovary carcinoma" OR "endometrium adenocarcinoma of ovary" OR "endometrium adenocarcinoma of the ovary" OR "ovarian endometrioid adenocarcinoma" OR "ovarian endometrioid cancer" OR "ovarian endometrioid carcinoma" OR "ovary endometrium adenocarcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Endometrioid carcinoma of ovary" OR "Endometrioid carcinoma of the ovary" OR "endometrioid adenocarcinoma of ovary" OR "endometrioid adenocarcinoma of the ovary" OR "endometrioid cancer of ovary" OR "endometrioid cancer of the ovary" OR "endometrioid ovary carcinoma" OR "endometrium adenocarcinoma of ovary" OR "endometrium adenocarcinoma of the ovary" OR "ovarian endometrioid adenocarcinoma" OR "ovarian endometrioid cancer" OR "ovarian endometrioid carcinoma" OR "ovary endometrium adenocarcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 66 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T16:42:53.153Z
